摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-氯-3-乙基苯并[b]噻吩 | 51828-46-7

中文名称
5-氯-3-乙基苯并[b]噻吩
中文别名
——
英文名称
5-chloro-3-ethylbenzo[b]thiophene
英文别名
5-chloro-3-ethyl-1-benzothiophene
5-氯-3-乙基苯并[b]噻吩化学式
CAS
51828-46-7
化学式
C10H9ClS
mdl
——
分子量
196.7
InChiKey
PCBVJMFXVRCIPE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    28.2
  • 氢给体数:
    0
  • 氢受体数:
    1

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-氯-3-乙基苯并[b]噻吩乙酰氯 在 aluminum (III) chloride 作用下, 以 二硫化碳 为溶剂, 以41%的产率得到1-(5-chloro-3-ethylbenzo[b]thiophen-2-yl)ethanone
    参考文献:
    名称:
    BENZOTHIOPHENE INHIBITORS OF RHO KINASE
    摘要:
    本发明涉及化合物和方法,这些化合物和方法可能作为Rho激酶的抑制剂在治疗或预防疾病方面有用。
    公开号:
    US20080021026A1
  • 作为产物:
    描述:
    1-(4-chlorophenylthio)butan-2-one 在 PPA 、 氢氧化钾 作用下, 以 氯苯 为溶剂, 以89%的产率得到5-氯-3-乙基苯并[b]噻吩
    参考文献:
    名称:
    BENZOTHIOPHENE INHIBITORS OF RHO KINASE
    摘要:
    本发明涉及化合物和方法,这些化合物和方法可能作为Rho激酶的抑制剂在治疗或预防疾病方面有用。
    公开号:
    US20080021026A1
点击查看最新优质反应信息

文献信息

  • BICYCLO [2.2.1] ACID GPR120 MODULATORS
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20160016880A1
    公开(公告)日:2016-01-21
    The present invention provides compounds of Formula (I): (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
    本发明提供了Formula (I)的化合物:(I)或其立体异构体,或其药用可接受的盐,其中所有变量如本文所定义。这些化合物是GPR120 G蛋白偶联受体调节剂,可用作药物。
  • [EN] 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS<br/>[FR] COMPOSES 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE POUR LE TRAITEMENT DE LA TUBERCULOSE
    申请人:OTSUKA PHARMA CO LTD
    公开号:WO2005042542A1
    公开(公告)日:2005-05-12
    The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1)in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and -(CH2)nR2 may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring), (30)and R2 represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria.
    本发明提供了一种由以下一般式表示的2,3-二氢-6-硝基咪唑[2,1-b]噁唑化合物:(1)在上述式(1)中,R1代表氢原子或C1-C6烷基,n代表0至6的整数,R1和-(CH2)nR2可以与下面的式(30)一起形成一个螺环,与相邻的碳原子一起(在下面的式中,RRR代表可能在哌啶环上具有取代基的哌啶基),(30)和R2代表苯并噻唑氧基、喹啉氧基、吡啶氧基或类似物。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型耐酸细菌具有出色的杀菌作用。
  • [EN] PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS<br/>[FR] PROCÉDÉ DE SYNTHÈSE DES COMPOSÉS ACIDES PHOSPHONIQUES ET PHOSPHINIQUES
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2009051746A1
    公开(公告)日:2009-04-23
    The present invention is directed to an improved process for synthesizing phosphonic and phosphinic acid chymase inhibitor compounds.
    本发明涉及一种改进的合成磷酸和膦酸基的胰蛋白酶抑制剂化合物的方法。
  • Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
    申请人:Akerman Michelle
    公开号:US20070142384A1
    公开(公告)日:2007-06-21
    The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula Q-L 1 -P-L 2 -M-X-L 3 -A wherein the definitions of the variables Q, L 1 , P, L 2 , M, X, L 3 and A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.
    本发明提供了一些化合物,例如用于调节受试者胰岛素水平的化合物,其具有以下一般式Q-L1-P-L2-M-X-L3-A,其中变量Q、L1、P、L2、M、X、L3和A的定义在此处提供。本发明还提供了该化合物的组合物和使用该化合物的方法,例如治疗II型糖尿病。
  • AMIDE DERIVATIVE OR SALT THEREOF
    申请人:Kaku Hidetaka
    公开号:US20090062363A1
    公开(公告)日:2009-03-05
    [Problem] To provide a compound which can be used for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that an amide derivative characterized by the possession of a nitrogen-containing bicyclic hetero ring (e.g., an indole or the like), or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT 2B receptor and 5-HT 7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).
    [问题] 提供一种可用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病的化合物,特别是用于治疗肠易激综合征(IBS)。 [解决方法] 发现一种具有含氮双环杂环(例如吲哚或类似物)的酰胺衍生物或其药学上可接受的盐具有强烈的5-HT2B受体和5-HT7受体的拮抗作用。此外,本发明的化合物具有对两种受体的拮抗活性,与仅使用选择性拮抗剂相比,表现出良好的药理作用。基于上述,本发明的化合物可用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病,特别是用于治疗肠易激综合征(IBS)。
查看更多

同类化合物